Joshua E. Schimmer

Joshua E. Schimmer Recent News

UPDATE: Piper Jaffray Initiates Coverage on Regeneron Pharmaceuticals as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on Vanda Pharmaceuticals on Expected Attractive Returns
UPDATE: Piper Jaffray Initiates Coverage on Pharmacyclics as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on MannKind on Expected Attractive Returns
UPDATE: Piper Jaffray Initiates Coverage on Incyte as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on Gilead Sciences on Expected Attractive Returns
UPDATE: Piper Jaffray Resumes Coverage on Celgene as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns
UPDATE: Piper Jaffray Resumes Coverage on Biogen Idec as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on Amgen on Expected Attractive Returns
UPDATE: Piper Jaffray Initiates Coverage on Alexion Pharmaceuticals as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on Nektar Therapeutics on Expected Attractive Returns
UPDATE: Piper Jaffray Initiates Coverage on Insmed as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on GW Pharmaceuticals on Expected Attractive Returns
UPDATE: Piper Jaffray Initiates Coverage on Chimerix as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on Repros Therapeutics on a Cleaner Approach to Male Hypogonadism
UPDATE: Piper Jaffray Assumes Coverage on ISIS Pharmaceuticals as Company's Antisense Platform Continues to Advance